Statement Of Cash Flows [Abstract]

AlzChem Group AG - Filing #6951715

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-01-01
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2020-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Interest paid, classified as operating activities
997,000 EUR
1,196 EUR
Interest received, classified as operating activities
10,000 EUR
180,000 EUR
Income taxes paid (refund), classified as operating activities
6,354 EUR
10,484 EUR
Other inflows (outflows) of cash, classified as operating activities
309,000 EUR
248,000 EUR
Cash flows from (used in) operating activities
43,016 EUR
48,710 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
56,000 EUR
3,000 EUR
Purchase of property, plant and equipment, classified as investing activities
28,535 EUR
28,832 EUR
Cash flows from (used in) investing activities
28,479 EUR
28,829 EUR
Cash flows from (used in) financing activities [abstract]
Payments to acquire or redeem entity's shares
1,013 EUR
0 EUR
Payments of other equity instruments
171,000 EUR
171,000 EUR
Proceeds from borrowings, classified as financing activities
0 EUR
10,000 EUR
Repayments of borrowings, classified as financing activities
12,704 EUR
11,934 EUR
Payments of lease liabilities, classified as financing activities
1,911 EUR
1,996 EUR
Dividends paid, classified as financing activities
7,821 EUR
7,632 EUR
Cash flows from (used in) financing activities
23,620 EUR
11,734 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
9,083 EUR
8,147 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
251,000 EUR
91,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
9,083 EUR
8,147 EUR
Cash and cash equivalents
8,285 EUR
17,117 EUR
17,117 EUR
9,061 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.